Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast:
What: Aastrom Biosciences, Inc. 4th Quarter Fiscal Year 2007 Investor Conference Call
When: Monday, September 10, 2007 @ 4:30 pm (EDT)
Where: http://www.vcall.com/IC/CEPage.asp?ID=119955
How: • For live Internet access, simply log on to the web at the address above.
• For phone access, interested parties should call toll-free (877) 407-9205 before the start of the call to register and identify themselves as registrants of the “Aastrom Conference Call”. Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8054.
• To download the podcast, simply log on to the web at the address above.
Contact: Investor Relations Department, (734) 930-5777 or mail@aastrom.com
If you are unable to participate during the live call, the webcast will be available for replay at http://www.investorcalendar.com/ until December 10, 2007. Through September 21, 2007, the audio replay of the call will be available by dialing toll-free (877) 660-6853, or from outside the U.S. (201) 612-7415. When prompted on the phone, the Account # is: 286, and the Conference ID# is: 252325.
Aastrom is a regenerative medicine company developing autologous cell products for the repair or regeneration of bone, vascular, cardiac and neural tissues, based on its proprietary Tissue Repair Cell (TRC) Technology. Aastrom's TRC-based products contain a unique cell mixture of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. TRC-based products have been used in over 250 patients to date and are being clinically evaluated for bone regeneration as a result of osteonecrosis of the femoral head (U.S.: ON-CORE Phase III trial and Spain: pivotal trial), and vascular regeneration related to critical limb ischemia (U.S.: RESTORE-CLI Phase IIb trial and Germany: Phase I/II trial). Aastrom has recently completed a U.S. Phase I/II severe fracture clinical trial, and is also developing programs to address cardiac and neural regeneration indications. TRC-based products have received Orphan Drug Designation from the FDA for use in the treatment of osteonecrosis of the femoral head and the treatment of dilated cardiomyopathy, a severe chronic disease of the heart.
For more information, visit Aastrom’s website at www.aastrom.com. (astmc)